// App-Quantinova.ai

: A phase 2, open-label study of neoadjuvant chemotherapy plus tislelizumab followed by radiotherapy-based, bladder-preserving treatment for high risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).

Researchers

Presenter

  • Feng Wen

Principal Investigators

  • Tianhai Lin

  • Peng Zhang

  • Ping Tan

  • Xiaonan Zheng

  • Yali Shen

Medical Centers

  • Sichuan University West China Hospital, Sichuan, China

  • Department of Urology/Institute of Urology, West China Hospital of Sichuan University, Chengdu, China

  • West China Hospital of Sichua University, Chengdu, China

  • West China Hospital of Sichua University, Chengdu, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Tislelizumab

  • Carboplatin

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved